Iceland· IS-EU/1/15/1024/004
KEYTRUDA
A pembrolizumab product containing pembrolizumabum inn, registered in Iceland by Merck Sharp & Dohme B.V.*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Pembrolizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FF02 (pembrolizumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Pembrolizumab · ATC L01FF02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pembrolizumab costs, country by country.
Normalised to the WHO defined daily dose (9.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pembrolizumab · price per daily dose (9.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$245.95
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Pembrolizumabum INN
- Manufacturer
- Merck Sharp & Dohme B.V.*
- Country
- Iceland (IS)
- ATC code
- L01FF02
- ATC class
- Pembrolizumab
- Defined daily dose
- 9.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean1052082,4 ml x1 hglISK 1145000
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
20 interactions on record for pembrolizumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pembrolizumab · interactions on record
20 records
- 3 severe
- 17 moderate
Most severe, free to view
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- PomalidomideL04AX06severe
- PrednisoloneA07EA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pembrolizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumKeytruda 395 mgMerck Sharp & Dohme
- CzechiaKEYTRUDAMerck Sharp & Dohme B.V., Haarlem
- NorwayKeytrudaMerck Sharp & Dohme B.V
- PolandKeytrudaMerck Sharp & Dohme B.V.
- SwedenKEYTRUDA 395 mg Injektionsvätska, lösningMerck Sharp & Dohme BV
- United KingdomKeytruda 100mg/4ml concentrate for solution for infusion vialsOriginalis B.V.
- SpainKEYTRUDA 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandKeytrudaMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Keytruda
- Norway · Keytruda
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/97924fe2-ce23-4367-859d-bb5ac9b5d52e GET /v1/drugs/97924fe2-ce23-4367-859d-bb5ac9b5d52e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FF02",
"marketed": true,
"strength": "395 mg",
"ma_number": "EU/1/15/1024/004",
"substance": "Pembrolizumabum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45978"
}See everything about pembrolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.